Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Nature medicine - 1 Jan 2019

Agarwal Rishu, Chan Yih-Chih, Tam Constantine S, Hunter Tane, Vassiliadis Dane, Teh Charis E, Thijssen Rachel, Yeh Paul, Wong Stephen Q, Ftouni Sarah, Lam Enid Y N, Anderson Mary Ann, Pott Christiane, Gilan Omer, Bell Charles C, Knezevic Kathy, Blombery Piers, Rayeroux Kathleen, Zordan Adrian, Li Jason, Huang David C S, Wall Meaghan, Seymour John F, Gray Daniel H D, Roberts Andrew W, Dawson Mark A, Dawson Sarah-Jane

Abstract excerpt

Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma. However, strategies to enable the evaluation of therapeutic response are required. Our prospective analyses of patients within the AIM study revealed genomic profiles that clearly dichotomized responders and nonresponders. Mutations in ATM were present in most patients who achieved a complete response, while chromosome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chronic Lymphocytic Leukemia Research

Share to Lymphoma Diagnosis and Treatment

Source

Identifiers

PMID: 30455436
DOI: 10.1038/s41591-018-0243-z

Genes

ATM
BCL2L1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaPMID 30455436Read ↗

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read ↗

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemiaSemantic proximity Read ↗

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.Semantic proximity Read ↗

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read ↗

Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma.Semantic proximity Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLSemantic proximity Read ↗

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLSemantic proximity Read ↗

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.Semantic proximity Read ↗

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.Semantic proximity Read ↗

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.